Phospho-CBX3 (Ser93) Antibody

What is Phospho-CBX3 (Ser93) Antibody and what epitope does it recognize?

Phospho-CBX3 (Ser93) Antibody is a polyclonal antibody that specifically detects endogenous levels of HP1γ (Heterochromatin Protein 1 gamma, also known as CBX3) only when phosphorylated at serine 93. The antibody is typically raised in rabbits using synthetic phosphopeptides containing the amino acid sequence around the phosphorylation site of Serine 93 (R-L-S(p)-L-S) derived from Human HP1γ . It's important to note that this site is sometimes referred to as Ser83 in some literature, which refers to the processed form of the protein, while Ser93 corresponds to the position in the unprocessed form . This antibody serves as a valuable tool for studying post-translational modifications of this important chromatin regulatory protein.

What are the recommended applications and dilutions for Phospho-CBX3 (Ser93) Antibody?

The Phospho-CBX3 (Ser93) Antibody has been validated for multiple experimental applications with specific recommended dilutions:

Researchers should optimize these dilutions for their specific experimental conditions, sample types, and detection methods to achieve optimal signal-to-noise ratios.

What species reactivity has been confirmed for Phospho-CBX3 (Ser93) Antibody?

The Phospho-CBX3 (Ser93) Antibody has demonstrated cross-reactivity with multiple species, making it versatile for comparative studies. According to multiple sources, the antibody has confirmed reactivity with:

• Human samples

• Mouse samples

• Rat samples

This cross-species reactivity is likely due to the high conservation of the phosphorylation site and surrounding amino acid sequences across these mammalian species. When using this antibody with other species not listed here, validation experiments should be performed to confirm specificity.

How should Phospho-CBX3 (Ser93) Antibody be stored and handled?

Proper storage and handling are crucial for maintaining antibody activity. The Phospho-CBX3 (Ser93) Antibody should be stored at -20°C or -80°C upon receipt . It's important to avoid repeated freeze-thaw cycles as this can degrade the antibody and reduce its specificity and sensitivity. The antibody is typically supplied in a buffer containing phosphate buffered saline (PBS, pH 7.4) with 50% glycerol, 0.02% sodium azide, and sometimes 0.5% BSA as stabilizers . When working with the antibody, aliquoting into smaller volumes for single-use applications is recommended to avoid repeated freezing and thawing of the stock solution.

What is the biological significance of CBX3 phosphorylation at Ser93?

The phosphorylation of CBX3/HP1γ at Ser93 (Ser83 in the processed form) has significant biological implications for gene regulation. Research indicates that this phosphorylation occurs on a subpopulation of HP1γ that is specifically associated with euchromatin, particularly HP1γ bound to coding regions of active genes . This phosphorylation appears to impair the ability of HP1γ to silence transcription and may serve as a marker for transcription elongation .

Phosphorylation at this site is regulated by protein kinase A (PKA) in vitro, and activation of PKA by forskolin and IBMX treatment leads to increased phosphorylation in vivo . Interestingly, this phosphorylation also increases during mitosis, as demonstrated by increased immunofluorescent staining in untreated mitotic cells and increased Western blot signal in lysates from cells arrested in mitosis by paclitaxel treatment . This suggests a cell cycle-dependent regulation of CBX3 function through this specific phosphorylation event.

How does CBX3 phosphorylation status affect its role in RNA processing and splicing regulation?

Recent genome-wide localization analysis has revealed that CBX3 binds to genic regions, with binding patterns strongly correlating with gene activity across multiple cell types . More importantly, CBX3 appears to play a crucial role in efficient RNA processing. Loss of CBX3 results in a decrease in transcript levels of specific target genes and, surprisingly, leads to an increase in unspliced transcripts .

Methodologically, researchers investigating the role of Ser93 phosphorylation in RNA processing should consider:

• Comparing binding profiles of total CBX3 versus phospho-CBX3 using ChIP-seq

• Analyzing the impact of phosphorylation-deficient mutants (S93A) on pre-mRNA splicing efficiency

• Conducting RNA immunoprecipitation experiments using phospho-specific antibodies to identify directly affected transcripts

• Performing RNA-seq with splice junction analysis after modulating CBX3 phosphorylation levels

• Assessing co-localization of phosphorylated CBX3 with splicing machinery components using super-resolution microscopy

The finding that loss of CBX3 diminishes the recruitment of splicing factors to gene bodies suggests that phosphorylation at Ser93 may regulate protein-protein interactions between CBX3 and components of the splicing machinery, potentially serving as a molecular switch that coordinates transcription with RNA processing.

What is the role of CBX3 phosphorylation in the IFNγ/STAT1/PD-L1 axis in cancer immunology?

Recent research has identified CBX3 as an antagonist of the IFNγ signaling cascade in the colon epithelium through repression of STAT1 and CD274 (PD-L1) transcription . ChIP-seq analysis revealed CBX3 binding at the promoter regions of both STAT1 and CD274 genes, and RNA-seq data confirmed that CBX3 knockout led to upregulation of these genes .

To investigate how phosphorylation at Ser93 might influence this pathway, researchers should consider:

• Comparing the binding affinity of phosphorylated versus non-phosphorylated CBX3 to STAT1 and CD274 promoters using ChIP-qPCR with phospho-specific antibodies

• Examining how PKA activators (which increase Ser93 phosphorylation) affect IFNγ-induced STAT1 and PD-L1 expression

• Generating phosphomimetic (S93D/E) and phospho-null (S93A) CBX3 mutants to assess their differential effects on IFNγ signaling

• Performing co-immunoprecipitation experiments to identify protein complexes associated with phosphorylated CBX3 in the context of IFNγ stimulation

Experimental evidence shows that CBX3 knockout in CRC cell lines significantly enhances STAT1 activation upon IFNγ stimulation, as demonstrated by increased phospho-STAT1 levels and dramatically upregulated PD-L1 expression . This suggests that CBX3 phosphorylation status could potentially modulate tumor immunogenicity and response to immunotherapy by regulating the IFNγ/STAT1/PD-L1 axis.

How can researchers distinguish between Ser83 and Ser93 phosphorylation sites in experimental design and data interpretation?

The literature contains references to both Ser83 and Ser93 phosphorylation sites in CBX3/HP1γ, creating potential confusion. Cell Signaling Technology notes that Ser83 refers to the same site as Ser93 in the unprocessed form of the protein . To address this nomenclature challenge, researchers should:

• Perform sequence alignment analysis to identify the exact position within different reference sequences

• Utilize synthetic phosphopeptides representing both numbered positions to validate antibody specificity

• Include phosphatase treatment controls to confirm signal specificity

• Clearly state which protein accession number and residue numbering system is being used in publications

• Consider mass spectrometry-based confirmation of the exact phosphorylation site

When designing site-directed mutagenesis experiments, researchers should ensure that the correct amino acid position is targeted based on the specific construct being used. When comparing results across studies, attention should be paid to which numbering system was used to avoid misinterpretation of data.

What techniques should be used to investigate CBX3 phosphorylation dynamics during cell cycle progression?

The search results indicate that phosphorylation of HP1γ/CBX3 on Ser93 increases during mitosis . To comprehensively investigate these dynamics, researchers should consider:

• Cell synchronization methods:

  • Double thymidine block for G1/S boundary

  • Thymidine-nocodazole treatment for G2/M

  • Mitotic shake-off for M phase

  • Serum starvation-stimulation for G0 to G1 transition

• Analytical approaches:

  • Western blotting with phospho-specific antibody across cell cycle stages

  • Immunofluorescence microscopy with co-staining for cell cycle markers

  • Flow cytometry with dual staining for DNA content and phospho-CBX3

  • Quantitative mass spectrometry to measure phosphorylation stoichiometry

• Chromatin association analysis:

  • Chromatin fractionation followed by Western blotting for phospho-CBX3

  • ChIP-seq at different cell cycle stages to map genomic binding dynamics

  • Sequential ChIP using cell cycle-specific histone marks followed by phospho-CBX3 IP

For Western blot experiments, forskolin treatment can serve as a positive control, as it activates PKA, which has been shown to phosphorylate CBX3 at Ser93 . Additionally, phosphatase treatment of cell lysates can be used as a negative control to confirm antibody specificity.

How can Phospho-CBX3 (Ser93) Antibody be effectively used in ChIP-seq experiments?

For researchers designing ChIP-seq experiments with Phospho-CBX3 (Ser93) Antibody, several methodological considerations are crucial:

• Antibody validation:

  • Perform peptide competition assays using the phosphopeptide immunogen

  • Include non-phosphorylated peptide controls to confirm phospho-specificity

  • Validate antibody in Western blot prior to ChIP application, using forskolin-treated cells as a positive control

• Experimental design:

  • Include parallel ChIP with total CBX3 antibody to determine the proportion of phosphorylated protein

  • Consider sequential ChIP (Re-ChIP) to identify genomic loci where CBX3 is specifically phosphorylated

  • Include appropriate positive controls (genes known to be bound by CBX3) and negative controls

• Data analysis:

  • Compare phospho-CBX3 binding patterns with euchromatin markers (like H3K4me3)

  • Integrate with RNA-seq data to correlate binding with gene expression

  • Look specifically at coding regions of active genes, where phosphorylated CBX3 has been reported to localize

Previous ChIP-seq studies have successfully mapped CBX3 binding sites genome-wide, revealing its enrichment at gene bodies of active genes and correlation with gene activity across multiple cell types . These findings provide a foundation for more detailed studies focusing specifically on the phosphorylated subpopulation of CBX3.

What experimental approaches can determine the functional consequences of CBX3 phosphorylation at Ser93?

To establish causal relationships between CBX3 phosphorylation at Ser93 and its functional consequences, researchers should consider:

• Generating phospho-mutant cell lines:

  • Phospho-null (S93A) mutations to prevent phosphorylation

  • Phosphomimetic (S93D/E) mutations to simulate constitutive phosphorylation

  • Use CRISPR/Cas9 knock-in approaches for endogenous mutation

• Functional assays:

  • RNA-seq with splicing analysis to assess effects on RNA processing

  • ChIP-seq to determine alterations in genomic binding patterns

  • Co-immunoprecipitation to identify phosphorylation-dependent protein interactions

  • Reporter gene assays to measure transcriptional repression activity

• Pathway analysis:

  • Assess effects on IFNγ signaling by measuring STAT1 activation and PD-L1 expression

  • Examine cell cycle progression using flow cytometry

  • Analyze chromatin compaction using accessibility assays

A particularly informative approach would be to compare the molecular phenotypes of phospho-null versus phosphomimetic mutants in the context of RNA processing defects and IFNγ signaling, as these have been identified as key functional areas affected by CBX3.

How does forskolin treatment affect CBX3 phosphorylation and what controls should be included in such experiments?

Forskolin is an activator of adenylyl cyclase that increases intracellular cAMP levels, thereby activating protein kinase A (PKA). Research has shown that PKA can phosphorylate HP1γ/CBX3 at Ser93 in vitro, and forskolin treatment increases this phosphorylation in vivo . When designing experiments using forskolin to modulate CBX3 phosphorylation:

• Dose and time optimization:

  • Titrate forskolin concentration (typically 10-50 μM)

  • Perform time-course experiments to determine optimal treatment duration

  • Consider co-treatment with IBMX (a phosphodiesterase inhibitor) to prevent cAMP degradation

• Essential controls:

  • Vehicle control (typically DMSO)

  • PKA inhibitor (e.g., H-89) to confirm PKA-dependent phosphorylation

  • Phosphatase treatment of lysates as a negative control for phospho-specific detection

  • Total CBX3 antibody blotting to ensure changes are in phosphorylation rather than protein levels

• Validation methods:

  • Western blot with phospho-specific antibody

  • Immunofluorescence to assess subcellular localization changes

  • Mass spectrometry to quantify phosphorylation stoichiometry and detect other potential modifications

The search results mention that Western blot analysis of extracts from K562 cells treated with forskolin using HP1γ (Phospho-Ser93) Antibody can serve as a positive control, with the specificity confirmed by treatment with antigen-specific peptide .

How can researchers investigate the relationship between CBX3 phosphorylation and its targeting to specific chromatin domains?

The search results indicate that phosphorylation at Ser93 occurs specifically on a subpopulation of HP1γ found associated with euchromatin, particularly HP1γ bound to coding regions of active genes . To investigate this relationship:

• Chromatin co-localization analysis:

  • Perform ChIP-seq with phospho-CBX3 antibody and compare with active chromatin marks (H3K4me3, H3K27ac, H3K36me3)

  • Conduct sequential ChIP (first with active or repressive histone marks, then with phospho-CBX3)

  • Use super-resolution microscopy with co-staining for phospho-CBX3 and chromatin markers

• In vitro binding assays:

  • Compare binding affinity of phosphorylated versus non-phosphorylated CBX3 to nucleosomes with different histone modifications

  • Perform peptide pulldowns using differentially modified histone tails

  • Use surface plasmon resonance to quantify binding kinetics

• Cellular fractionation:

  • Biochemically separate euchromatin and heterochromatin fractions

  • Analyze distribution of phosphorylated versus total CBX3 in each fraction

  • Compare results across different cell cycle stages

Understanding how phosphorylation affects CBX3's chromatin targeting could provide insights into its dual roles in transcriptional regulation and RNA processing, particularly in the context of the IFNγ/STAT1/PD-L1 axis in cancer cells and its broader functions in genome-wide RNA processing .